Posted by Michael Wonder on 01 Jun 2020
Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)
29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) for the treatment of patients of all ages with mucopolysaccharidosis type IVA (MPS IVA) also called Morquio A syndrome.
The comparison alternative to Vimizim is best supportive care, which consists of symptom-relieving drug treatment and surgery to correct skeletal changes.
Vimizim is dosed once a week and the drug cost per year is estimated to be between about 3.3 and 6.6 million. This should be compared to the cost of symptom-relieving drug treatment and surgery.
